Drug Guide
 

Ticagrelor

Bookmark
  •  
    Oral
    Ticagrelor
    Brilinta 
     
    Directly inhibits P2Y12 receptors, and does not require enzymatic activation.
    • Mechanism of Action
    • Irreversibly inhibits the binding of adenosine diphosphate (ADP) to platelet P2Y₁₂ receptors, resulting in reduced platelet activation and aggregation.
    • Pharmacology
    • Directly inhibits P2Y12 receptors, and does not require enzymatic activation.

Clinical Use

    • Indications
    • Acute coronary syndrome (in conjunction with aspirin)
    • Prevention of in-stent thrombosis following percutaneous coronary intervention
    • Contraindications
    • Active bleeding
    • Intracranial haemorrhage
    • Adverse Effects
    • Haemorrhage.
Want more info like this?
  • Your electronic clinical medicine handbook
  • Guides to help pass your exams
  • Tools every medical student needs
  • Quick diagrams to have the answers, fast
  • Quizzes to test your knowledge
Explore
   
 
Feedback